Abstracts cancer, and the general population, respectively (0 = worst; 52 = least fatigue). Ten-year total per patient costs (drug, monitoring, physician visits, adverse events) for managing GIST patients with molecularly targeted treatment were estimated at £47,086-£70,811 compared to £3674-£4230 with best supportive care. CONCLUSIONS: Data suggest the incidence of GIST is similar across countries; lower incidence in one study is likely explained by differences in method of case ascertainment. Although patients with GIST present with fatigue comparable to other cancers, additional research is needed to comprehensively understand its HRQL burden. The increased cost associated with new therapies must be balanced against their expected benefits. 
PCN3 EPIDEMIOLOGIC, HUMANISTIC AND ECONOMIC BURDEN OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
Pfizer, New York, NY, USA OBJECTIVE: Renal cell carcinoma has an asymptomatic course and 25-30% of patients present with metastatic disease at time of diagnosis. Molecularly targeted therapies (MTTs) represent a breakthrough in treatment of mRCC, prolonging life, reducing toxicity and the negative impact of treatment on health-related quality of life (HRQOL), and offering viable therapeutic options to a broader patient population relative to immunotherapy. The objective of this study was to explore the burden of mRCC and the potential clinical, economic and humanistic value of MTTs. METHODS: PubMed, scientific meeting and online databases were searched for articles relating to the epidemiologic, humanistic and economic burden of mRCC. Thirty-five articles were selected. Epidemiology and economic statistics for mRCC were estimated from international registries and published data sources. RESULTS: Approximately 1500-8600 new mRCC cases occur annually in major European and North American countries, and Japan. Standard immunotherapy is largely ineffective (less than 10% response rates; no benefit in most patients, especially the elderly) despite a high annual cost of treatment (e.g., $15,500-$82,000 across countries). In the absence of effective treatment, mRCC is rapidly fatal with 13% or fewer patients surviving and a median survival of less than 1 year. Two-year costs of care for mRCC have been estimated at $35,735/year (US$). HRQOL of mRCC patients is comparable to congestive heart failure, diabetes and other cancer patients and may be further diminished by systemic immunotherapy. Recent studies show that MTTs produce marked improvements in response rates/survival, and tolerability without negative impact on HRQL. CONCLUSIONS: The need for MTTs for mRCC is characterized by the lack of effective treatment for the vast majority of patients, high mortality, and considerable humanistic and economic burden. Meaningful improvements in effectiveness and tolerability in this patient population suggest that MTTs offer economic and humanistic value in the treatment of mRCC.
PCN4 A COMPARATIVE BUDGET IMPACT (BI) ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) 500 mG Q3W VERSUS OTHER ERYTHROPOIESIS STIMULATING PROTEINS (ESP) IN CHEMOTHERAPY-INDUCED ANEMIA (CIA) IN SPAIN
Pérez Alcántara F 1 , Badia X 2 , Arocho R 3 1 Health Outcomes Research, Barcelona, Spain, 2 Health Outcomes Research Europe, Barcelona, Spain, 3 Amgen SA, Barcelona, Spain ESP are standard treatment options for CIA. In this setting, both Epoetin (EPO) alfa and EPObeta are administered three times/week (TIW) or once/week (QW), while darbepoetin alfa (DA) is the only ESP approved to be administered as once every three weeks (Q3W). For ESP administered TIW or QW the SPCs states to double the dose if hemoglobine increases <1 g/dL after 4 weeks. Doubling the dose is not needed with starting dose DA 500 μg Q3W. These administration differences might result in different treatment costs for each agent. OBJECTIVE: Estimate BI (mean cost/patient) of administering the different ESP in the treatment of CIA in Spain. METHODS: The following variables were considered in the economic model: ESP ex-manufacturer price in Spain, administration pattern, weeks of treatment (12 weeks), weeks of evaluation before increments of dose (4 weeks), dose increases, and overall cost of one administration (€59.72). In addition, a two-way sensitivity analysis was performed to test the robustness of the results, considering the following variables: 1) administration cost from a minimum of 0 to +25%, and 2) the lowest and highest percentage of patients needing to increase dose for EPOalfa and EPObeta from six studies found in the literature where this data was reported. RESULTS: In the base case scenario, assuming an incidence of doubling the dose with both EPOalfa and EPObeta of 29.60%, which was the mean value found in the literature (min 22.90%, max 42.80%), treatment with starting dose DA 500 mg Q3W resulted in a BI that were 35.64% and 27.64% lower than EPOalfa 10,000 UI TIW and 40,000 UI QW respectively and 35.59% and 17.11% lower than EPObeta 10,000 UI TIW and 30,000 UI QW respectively. The results of the base case did not change in any of the sensitivity scenarios. CONCLUSION: The model shows that treatment of CIA with starting dose DA 500 mg Q3W is the rapeutic strategy with lower mean cost per patient for all the analyzed scenarios in Spain. 3 Photocure ASA, Oslo, Norway OBJECTIVE: Development of a decision analytic model to estimate the budget impact on the Swedish health service of using a more effective diagnostic tool in conjunction with white light cystoscopy (WLC) in the management of superficial bladder cancer (SBC). Hexvix (hexaminolevulinate) fluorescence cystoscopy potentially allows more complete detection and delineation of tumours compared with WLC in bladder cancer diagnosis. METHODS: Model inputs, including procedure costs and clinical algorithms, are based on the bladder cancer diagnosis and treatment guidelines of the European Association of Urology (EAU), literature review and Swedish clinical practice. Several trials report less residual tumour at early re-resection following 5-ALA fluorescence-assisted TURB with 59% to 80% relative reduction in recurrence in the fluorescence group compared to WLC. Based on these findings, the model assumed a conservative 40% reduction in recurrence rate when Hexvix was used alongside WLC to guide TURB. The model projects the flow of all newly diagnosed SBC patients, following histological risk classification at first TURB, through treatment one year after diagnosis. It covers Hexvix use in the operating room to guide first TURB in all patients with suspicion of bladder cancer and all follow-up TURBs in patients with recurrent SBC. RESULTS: In the Swedish population of newly diagnosed bladder cancer patients, the model projects a reduction in the number of procedures required in the first year compared to WLC alone, i.e. 29 cystectomies and 1961 TURBs with Hexvix compared to 52 and 2141 with WLC. Avoidance of these procedures would result in $212,895 (SEK 1,561,908) reduction in costs to the Swedish health service the first year after diagnosis. CONCLU-SIONS: The model predicts that use of Hexvix as an adjunct to WLC for all initial and follow-up TURBs in the first year following diagnosis will result in substantial cost savings for the Swedish health service.
PCN5 HEXVIX FLUORESCENCE CYSTOSCOPY FOR SUPERFICIAL BLADDER CANCER DIAGNOSIS: ANALYSIS OF BUDGET IMPACT ON THE SWEDISH HEALTH SERVICE

